2026-04-15 · medications, glp-1, semaglutide, tirzepatide, comparison

Semaglutide vs Tirzepatide

If you are weighing semaglutide (Wegovy) against tirzepatide (Zepbound), you are looking at the two most studied injectable medications for chronic weight management. Both are once-weekly injections, both work on gut hormone pathways, and both have produced meaningful weight loss in large clinical trials. The right fit depends on your medical history, your goals, insurance coverage, and how your body tolerates each drug.

Who this is for / not for

Good fit if:

• You meet medical criteria for chronic weight management and your clinician has recommended a GLP-1 class medication.
• You can commit to weekly injections, gradual dose increases, and ongoing follow-up visits.
• You want an evidence-based option with published trial data and clinician oversight.

Not a fit if:

• You have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2).
• You have had pancreatitis or severe gastrointestinal disease without clinician clearance.
• You are pregnant, breastfeeding, or planning pregnancy in the near future.
• You want a short-term, quick-fix solution. These are chronic therapies, and stopping usually leads to weight regain.

What each medication is

Semaglutide is a GLP-1 receptor agonist. It is sold as Wegovy for chronic weight management and as Ozempic for type 2 diabetes. It was the first once-weekly GLP-1 approved at higher doses specifically for weight loss, so it has the longest real-world track record among the newer generation of weight loss injections.

Tirzepatide is a dual GIP and GLP-1 receptor agonist. It is sold as Zepbound for chronic weight management and as Mounjaro for type 2 diabetes. Tirzepatide activates two gut hormone pathways instead of one, which may explain the larger average weight loss seen in its trials.

For a plain-language introduction to this drug class, see our GLP-1 weight loss overview.

How they work

Both drugs mimic hormones your gut naturally releases after eating. Semaglutide activates the GLP-1 receptor alone, which slows stomach emptying, increases feelings of fullness, and reduces appetite signals in the brain. Tirzepatide activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. The dual action is thought to add a second appetite and metabolic pathway on top of the GLP-1 effect.

In practice, both medications help most users eat less, feel full sooner, and reduce cravings. The mechanism is not a stimulant, a fat blocker, or a laxative. It is a signal change in how hunger is regulated.

Expected weight loss

Clinical trial averages give a useful reference, though individual results vary.

• Semaglutide: In the STEP 1 trial published in the New England Journal of Medicine, adults with overweight or obesity on 2.4 mg semaglutide lost an average of roughly 15 percent of total body weight by 68 weeks, compared with about 2.4 percent on placebo. Real-world results often fall in the 10 to 15 percent range over a similar timeline.
• Tirzepatide: In the SURMOUNT-1 trial published in the New England Journal of Medicine, adults on tirzepatide (at 5 mg, 10 mg, and 15 mg doses) lost an average of roughly 15 to 22 percent of total body weight at 72 weeks, compared with about 3 percent on placebo. The highest dose produced the largest average loss.

Head-to-head data in people with type 2 diabetes (SURPASS-2) also suggested tirzepatide produced greater weight reduction than semaglutide at the doses studied. That said, trial averages are not promises. Adherence, lifestyle changes, and individual biology all affect real-world outcomes.

Side effects and safety

The side effect profiles of semaglutide and tirzepatide are similar.

Common side effects (both drugs):

• Nausea, especially during dose escalation
• Diarrhea or constipation
• Vomiting
• Decreased appetite and early fullness
• Fatigue, headaches, and injection site reactions

Most gastrointestinal effects are mild to moderate and tend to improve as the body adjusts. Slow titration, smaller meals, and staying hydrated can help.

Serious but less common risks (both drugs):

• Pancreatitis
• Gallbladder disease, including gallstones
• Kidney injury from dehydration related to vomiting or diarrhea
• Hypoglycemia, mainly in people who also take insulin or sulfonylureas
• Allergic reactions

Boxed warning (both drugs):

• Thyroid C-cell tumors, including medullary thyroid carcinoma, have been seen in rodent studies. Both medications carry a boxed warning and are contraindicated in people with a personal or family history of medullary thyroid cancer or MEN2.

For a deeper look at GLP-1 specific side effects, see our guide to ozempic side effects and the broader weight loss drug safety overview.

Dosing and administration

Both medications are weekly subcutaneous injections delivered with a pen device, typically in the abdomen, thigh, or upper arm. Both use a gradual dose titration designed to reduce side effects.

• Semaglutide (Wegovy): Starts at 0.25 mg weekly and titrates up approximately every 4 weeks to a maintenance dose of 2.4 mg weekly. Full titration usually takes about 4 to 5 months.
• Tirzepatide (Zepbound): Starts at 2.5 mg weekly and titrates up approximately every 4 weeks toward maintenance doses of 5 mg, 10 mg, or 15 mg weekly. The maintenance dose depends on tolerance and response.

You should not skip doses to accelerate weight loss or jump dose levels on your own. Clinicians adjust speed of titration if nausea or other symptoms are significant.

Cost and access

In the United States, list prices for both medications are in the low four figures per month before insurance. Actual out-of-pocket costs vary widely based on coverage.

• Insurance: Many commercial plans cover GLP-1 medications for weight loss only with prior authorization, documented BMI criteria, and evidence of prior lifestyle attempts. Some plans cover only the diabetes indication. Medicare coverage for obesity-only indications remains limited.
• Manufacturer savings programs: Eligible patients with commercial insurance may reduce monthly costs through manufacturer savings cards. Programs change, so confirm current terms directly with the manufacturer.
• Supply: Both medications have experienced shortages in recent years, which affects dose availability.
• Compounded GLP-1s: Compounded versions of semaglutide and tirzepatide are sold by some pharmacies and online clinics. These products are not FDA approved, are not evaluated for the same quality and purity as the branded drugs, and have been associated with dosing errors and adverse events. The FDA has issued warnings about compounded GLP-1 products. Treat them as outside the evidence base unless a qualified clinician has specifically recommended one to you.

How to choose

Use this checklist to guide a conversation with your clinician.

• Medical history. A personal or family history of medullary thyroid cancer, MEN2, pancreatitis, or severe GI disease can rule out one or both options.
• Weight loss goal. If your goal is the largest possible average reduction and you tolerate the class well, tirzepatide has produced larger trial averages. If you want the option with the longest weight management track record, semaglutide has more real-world years behind it.
• Insurance and cost. Call your plan first. Coverage, prior authorization criteria, and formulary placement often decide which drug is realistic.
• Side effect tolerance. Both drugs share a similar GI profile. If you have a history of significant nausea or reflux, plan for slower titration and dietary support.
• Other conditions. People with type 2 diabetes may have additional coverage options and should factor in glycemic goals. Coordinate with the prescriber who manages diabetes medications to avoid hypoglycemia.
• Long-term plan. Both drugs are chronic therapies. Choose the option you can realistically stay on and afford over time, since stopping commonly leads to regain.

Frequently asked questions

Can I switch from semaglutide to tirzepatide, or the other way around? Switching is possible and is done under clinician guidance. Your prescriber will decide the safest starting dose on the new drug based on your current dose, tolerance, and goals. Do not switch on your own, and never combine the two.

Which one loses more weight? In their respective phase 3 trials, tirzepatide produced a larger average percentage of body weight loss than semaglutide. In a head-to-head diabetes trial (SURPASS-2), tirzepatide also produced greater weight reduction than semaglutide. Individual results still vary widely, and averages are not guarantees.

Which has the longer track record? Semaglutide has been in use for type 2 diabetes since 2017 and for chronic weight management (as Wegovy) since 2021. Tirzepatide was approved for type 2 diabetes in 2022 and for chronic weight management (as Zepbound) in 2023. Semaglutide therefore has more years of post-approval data.

Are semaglutide and tirzepatide interchangeable? No. They are different molecules with different mechanisms, different dosing schedules, and different titration plans. A prescription is specific to one drug and one dose.

Do you regain weight after stopping? In trials where participants stopped the medication, most regained a substantial portion of the weight they had lost within about a year. Chronic weight management usually requires ongoing therapy, lifestyle support, or both to maintain results.

Are they safe for people with type 2 diabetes? Both semaglutide (as Ozempic) and tirzepatide (as Mounjaro) are FDA approved for type 2 diabetes. People who use insulin or sulfonylureas need careful dose planning to reduce the risk of hypoglycemia. Decisions should be coordinated with the clinician managing your diabetes.

Can I use a compounded version to save money? Compounded semaglutide and tirzepatide are not FDA approved. Quality, purity, and dosing accuracy are not guaranteed, and adverse events have been reported. Savings programs, manufacturer assistance, or insurance appeals are safer first steps.

Practical next steps

This week

• Check your insurance formulary and prior authorization criteria for both Wegovy and Zepbound.
• Write down your medical history, current medications, and any personal or family history of thyroid cancer or pancreatitis.
• Note your weight management goals and how you respond to nausea, since that may guide titration.

At your appointment

• Ask whether either drug is clearly preferred given your conditions.
• Ask about the titration plan, how to manage side effects, and what labs will be checked.
• Confirm the monitoring schedule and what to do if you miss a dose.

What to track

• Weekly weight trend rather than daily fluctuations.
• Appetite, fullness, and energy levels.
• Any persistent GI symptoms, abdominal pain, or changes in mood.

How this article was researched

We reviewed the published phase 3 clinical trials for semaglutide (STEP program) and tirzepatide (SURMOUNT program) in the New England Journal of Medicine, JAMA, and The Lancet, along with the FDA prescribing information for Wegovy and Zepbound. We focused on peer-reviewed primary evidence for expected weight loss, safety, dosing, and known contraindications.